Mark T. Brown

3.8k total citations · 1 hit paper
55 papers, 2.8k citations indexed

About

Mark T. Brown is a scholar working on Pharmacology, Rheumatology and Surgery. According to data from OpenAlex, Mark T. Brown has authored 55 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 18 papers in Rheumatology and 16 papers in Surgery. Recurrent topics in Mark T. Brown's work include Inflammatory mediators and NSAID effects (23 papers), Osteoarthritis Treatment and Mechanisms (17 papers) and Pain Mechanisms and Treatments (9 papers). Mark T. Brown is often cited by papers focused on Inflammatory mediators and NSAID effects (23 papers), Osteoarthritis Treatment and Mechanisms (17 papers) and Pain Mechanisms and Treatments (9 papers). Mark T. Brown collaborates with scholars based in United States, United Kingdom and France. Mark T. Brown's co-authors include Kenneth M. Verburg, Richard Langford, Andrew Whelton, Nancy A. Nussmeier, Christine R. West, Joel L. Parlow, Steven W. Boyce, Andreas Hoeft, Michael D. Smith and Isabelle Davignon and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mark T. Brown

55 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery

2005 808 citations Nancy A. Nussmeier, Andrew Whelton et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark T. Brown United States	25	1.2k	692	480	464	402	55	2.8k
Ryo Ogawa Japan	32	195 0.2×	1.2k 1.8×	236 0.5×	485 1.0×	350 0.9×	271	4.4k
Christine R. West United States	29	1.1k 0.9×	314 0.5×	927 1.9×	837 1.8×	74 0.2×	70	2.6k
Steven B. Cannady United States	25	138 0.1×	1.2k 1.8×	135 0.3×	597 1.3×	157 0.4×	119	2.7k
Satoshi Suzuki Japan	24	279 0.2×	875 1.3×	765 1.6×	169 0.4×	144 0.4×	200	3.2k
Christopher J. Winfree United States	24	114 0.1×	471 0.7×	90 0.2×	245 0.5×	198 0.5×	65	2.6k
Almut Grenz Germany	29	166 0.1×	583 0.8×	82 0.2×	350 0.8×	375 0.9×	50	3.6k
Fausto Iannotti United Kingdom	32	173 0.1×	496 0.7×	54 0.1×	333 0.7×	191 0.5×	63	3.9k
M Yoshizumi Japan	23	117 0.1×	474 0.7×	747 1.6×	1.0k 2.2×	685 1.7×	50	3.4k
Michael P. Murphy United States	24	334 0.3×	848 1.2×	66 0.1×	1.5k 3.2×	244 0.6×	72	3.6k

Countries citing papers authored by Mark T. Brown

Since Specialization

Citations

This map shows the geographic impact of Mark T. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Brown more than expected).

Fields of papers citing papers by Mark T. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Brown. The network helps show where Mark T. Brown may publish in the future.

Co-authorship network of co-authors of Mark T. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Brown. A scholar is included among the top collaborators of Mark T. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Brown. Mark T. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Mark T., David R. Cornblath, Martin Koltzenburg, et al.. (2023). Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clinical Drug Investigation. 43(7). 551–563. 3 indexed citations

Fallon, Marie, Maciej Sopata, Mark T. Brown, et al.. (2021). LBA62 Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. Annals of Oncology. 32. S1339–S1339. 3 indexed citations

Mont, Michael A., John A. Carrino, Aimee Burr, et al.. (2020). Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study. Osteoarthritis and Cartilage. 28. S29–S29. 1 indexed citations

Schnitzer, Thomas J., Arifulla Khan, Louis Bessette, et al.. (2020). Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study. Seminars in Arthritis and Rheumatism. 50(3). 387–393. 15 indexed citations

Birbara, C., Eugene J Dabezies, Aimee Burr, et al.. (2018). Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. Journal of Pain Research. Volume 11. 151–164. 28 indexed citations

Roemer, Frank W., Colin G. Miller, Christine R. West, et al.. (2017). Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment. Seminars in Arthritis and Rheumatism. 47(3). 323–330. 12 indexed citations

Schnitzer, Thomas J., Evan F. Ekman, Egilius L.H. Spierings, et al.. (2014). Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Annals of the Rheumatic Diseases. 74(6). 1202–1211. 123 indexed citations

Gimbel, Joseph, Alan Kivitz, Candace Bramson, et al.. (2014). Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain. 155(9). 1793–1801. 44 indexed citations

Bălănescu, Andra, Eugen Feist, G Wolfram, et al.. (2013). Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Annals of the Rheumatic Diseases. 73(9). 1665–1672. 76 indexed citations

10.

Spierings, Egilius L.H., et al.. (2013). A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 154(9). 1603–1612. 103 indexed citations

11.

Apfelbaum, Jeffrey L., Paul J. Desjardins, Mark T. Brown, & Kenneth M. Verburg. (2008). Multiple-day Efficacy of Parecoxib Sodium Treatment in Postoperative Bunionectomy Pain. Clinical Journal of Pain. 24(9). 784–792. 24 indexed citations

12.

Viscusi, Eugene R., Joseph Gimbel, Andreas M. Halder, et al.. (2008). A Multiple-Day Regimen of Parecoxib Sodium 20 mg Twice Daily Provides Pain Relief After Total Hip Arthroplasty. Anesthesia & Analgesia. 107(2). 652–660. 19 indexed citations

13.

Nussmeier, Nancy A., Andrew Whelton, Mark T. Brown, et al.. (2006). Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery. Anesthesiology. 104(3). 518–526. 116 indexed citations

14.

Nussmeier, Nancy A., Andrew Whelton, Mark T. Brown, et al.. (2005). Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. New England Journal of Medicine. 352(11). 1081–1091. 808 indexed citations breakdown →

15.

Nussmeier, Nancy A., et al.. (2005). Complications of the Cox-II inhibitors parecoxib and valdecoxib after cardiac surgery. Journal of Vascular Surgery. 42(6). 1242–1242. 1 indexed citations

16.

Hajós, Mihály, et al.. (2004). The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile. CNS Drug Reviews. 10(1). 23–44. 175 indexed citations

17.

Brown, Mark T.. (1999). ★★Microsurgical Reconstruction of the Cancer Patient. Otolaryngology. 120(1). A1–A1. 2 indexed citations

18.

Bigner, Darell D., Mark T. Brown, Allan H. Friedman, et al.. (1998). Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.. Journal of Clinical Oncology. 16(6). 2202–2212. 154 indexed citations

19.

Cheney, Mack L., Cliff A. Megerian, Mark T. Brown, & Michael J. McKenna. (1995). Mastoid obliteration and lining using the temporoparietal fascial flap. The Laryngoscope. 105(9). 1010–1013. 24 indexed citations

20.

Brown, Mark T., et al.. (1993). Progressive Sensorineural Hearing Loss in Association With Distal Renal Tubular Acidosis. Archives of Otolaryngology - Head and Neck Surgery. 119(4). 458–460. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact